Rapid optimization of drug combinations for the optimal angiostatic treatment of cancer

Angiogenesis

Volumn 18, Issue 3, 2015, Pages 233-244

  Weiss, Andrea ^a,b   Ding, Xianting ^c   van Beijnum, Judy R ^b   Wong, Ieong ^d   Wong, Tse J ^b   Berndsen, Robert H ^a,b   Dormond, Olivier ^e   Dallinga, Marchien ^f   Shen, Li ^g   Schlingemann, Reinier O ^f   Pili, Roberto ^g   Ho, Chih Ming ^d   Dyson, Paul J ^a   van den Bergh, Hubert ^a   Griffioen, Arjan W ^b   Nowak Sliwinska, Patrycja ^a,b  

^a EPFL   (Switzerland)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c SHANGHAI JIAO TONG UNIVERSITY   (China)

^d Engineering IV   (United States)

^e LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^f ACADEMIC MEDICAL CENTER   (Netherlands)

^g ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Anti angiogenesis; Combination therapy; Drug drug interactions; Feedback system control; Search algorithm

Indexed keywords

ANGINEX; ANGIOGENESIS INHIBITOR; AXITINIB; BEVACIZUMAB; DACTOLISIB; ERLOTINIB; HIGH MOBILITY GROUP B1 PROTEIN ANTIBODY; RAPTA C; SUNITINIB; UNCLASSIFIED DRUG; VIMENTIN ANTIBODY; ANTINEOPLASTIC AGENT; CD31 ANTIGEN; DICHLORO(4-CYMENE)(1,3,5-TRIAZA-7-PHOSPHATRICYCLO(3.3.1.1)DECANE)RUTHENIUM(II); IMIDAZOLE DERIVATIVE; ORGANOMETALLIC COMPOUND; QUINOLINE DERIVATIVE;

ADULT; ALGORITHM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SIZE; CAPILLARY DENSITY; CELL SPECIFICITY; CELL VIABILITY; CHORIOALLANTOIS; COLORECTAL CARCINOMA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SCREENING; ENDOTHELIUM CELL; FEEDBACK SYSTEM; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MIGRATION INHIBITION; MONOTHERAPY; MOUSE; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; STATISTICAL ANALYSIS; TUMOR XENOGRAFT; ANIMAL; APOPTOSIS; CANCER TRANSPLANTATION; CELL CULTURE TECHNIQUE; CELL MOTION; CELL SURVIVAL; CHICKEN; CYTOLOGY; MARKOV CHAIN; METABOLISM; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NUDE MOUSE; OVARY TUMOR; PATHOLOGY; TUMOR CELL LINE; VASCULARIZATION;

ALGORITHMS; ANIMALS; ANTIGENS, CD31; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; CHICKENS; CHORIOALLANTOIC MEMBRANE; DRUG SCREENING ASSAYS, ANTITUMOR; ENDOTHELIAL CELLS; FEEDBACK; FEMALE; HUMANS; IMIDAZOLES; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; ORGANOMETALLIC COMPOUNDS; OVARIAN NEOPLASMS; QUINOLINES; STOCHASTIC PROCESSES;

EID: 84931563239     PISSN: 09696970     EISSN: 15737209     Source Type: Journal    
DOI: 10.1007/s10456-015-9462-9     Document Type: Article

References (57)

1. Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285(21):1182–1186
2. Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407(6801):249–257
3. Gonzalez-Angulo AM, Hortobagyi GN, Ellis LM (2011) Targeted therapies: peaking beneath the surface of recent bevacizumab trials. Nat Rev Clin Oncol 8(6):319–320
4. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, Varela I, Phillimore B, Begum S, McDonald NQ, Butler A, Jones D, Raine K, Latimer C, Santos CR, Nohadani M, Eklund AC, Spencer-Dene B, Clark G, Pickering L, Stamp G, Gore M, Szallasi Z, Downward J, Futreal PA, Swanton C (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366(10):883–892
5. Hoey T (2010) Drug resistance, epigenetics, and tumor cell heterogeneity. Sci Transl Med 2(28):28ps19
6. Hayman SR, Leung N, Grande JP, Garovic VD (2012) VEGF inhibition, hypertension, and renal toxicity. Curr Oncol Rep 14(4):285–294
7. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS (2009) Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15(3):232–239
8. Loges S, Schmidt T, Carmeliet P (2010) Mechanisms of resistance to anti-angiogenic therapy and development of third-generation anti-angiogenic drug candidates. Genes Cancer 1(1):12–25
9. van Beijnum JR, Nowak-Sliwinska P, Huijbers EJ, Thijssen VL, Griffioen AW (2015) The great escape; the hallmarks of resistance to anti-angiogenic therapy. Pharmacol Rev 67:1–21
10. Griffioen AW, Molema G (2000) Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol Rev 52(2):237–268
11. Lignet F, Calvez V, Grenier E, Ribba B (2013) A structural model of the VEGF signalling pathway: emergence of robustness and redundancy properties. Math Biosci Eng 10(1):167–184
12. Griffioen AW, Weiss A, Berndsen RH, Abdul UK, Te Winkel MT, Nowak-Sliwinska P (2014) The emerging quest for the optimal angiostatic combination therapy. Biochem Soc Trans 42(6):1608–1615
13. Misale S, Arena S, Lamba S, Siravegna G, Lallo A, Hobor S, Russo M, Buscarino M, Lazzari L, Sartore-Bianchi A, Bencardino K, Amatu A, Lauricella C, Valtorta E, Siena S, Di Nicolantonio F, Bardelli A (2014) Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer. Sci Transl Med 6(224):224ra226
14. Sen B, Peng S, Tang X, Erickson HS, Galindo H, Mazumdar T, Stewart DJ, Wistuba I, Johnson FM (2012) Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib. Sci Transl Med 4(136):136ra170
15. Lehar J, Krueger AS, Avery W, Heilbut AM, Johansen LM, Price ER, Rickles RJ, Short GF 3rd, Staunton JE, Jin X, Lee MS, Zimmermann GR, Borisy AA (2009) Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nat Biotechnol 27(7):659–666
16. Bozic I, Reiter JG, Allen B, Antal T, Chatterjee K, Shah P, Moon YS, Yaqubie A, Kelly N, Le DT, Lipson EJ, Chapman PB, Diaz LA Jr, Vogelstein B, Nowak MA (2013) Evolutionary dynamics of cancer in response to targeted combination therapy. Elife 2:e00747
17. Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, Bergethon K, Shaw AT, Gettinger S, Cosper AK, Akhavanfard S, Heist RS, Temel J, Christensen JG, Wain JC, Lynch TJ, Vernovsky K, Mark EJ, Lanuti M, Iafrate AJ, Mino-Kenudson M, Engelman JA (2011) Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Trans Med 3(75):75ra26
18. Feldman DR, Baum MS, Ginsberg MS, Hassoun H, Flombaum CD, Velasco S, Fischer P, Ronnen E, Ishill N, Patil S, Motzer RJ (2009) Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 27(9):1432–1439
19. Spreafico A, Chi KN, Sridhar SS, Smith DC, Carducci MA, Kavsak P, Wong TS, Wang L, Ivy SP, Mukherjee SD, Kollmannsberger CK, Sukhai MA, Takebe N, Kamel-Reid S, Siu LL, Hotte SJ (2014) A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients. Invest New Drugs 32(5):1005–1016
20. Mayer LD, Janoff AS (2007) Optimizing combination chemotherapy by controlling drug ratios. Mol Interv 7(4):216–223
21. Pritchard JR, Lauffenburger DA, Hemann MT (2012) Understanding resistance to combination chemotherapy. Drug Resist Update 15(5–6):249–257
22. Wong PK, Yu F, Shahangian A, Cheng G, Sun R, Ho CM (2008) Closed-loop control of cellular functions using combinatory drugs guided by a stochastic search algorithm. Proc Natl Acad Sci 105(13):5105–5110
23. Price KV, Storn RM, Lampinen JA (2005) Differential evolution: a practical approach to global optimization. Natural computing series. Springer, Berlin
24. Calzolari D, Bruschi S, Coquin L, Schofield J, Feala JD, Reed JC, McCulloch AD, Paternostro G (2008) Search algorithms as a framework for the optimization of drug combinations. PLoS Comput Biol 4(12):e1000249
25. Dancey JE, Chen HX (2006) Strategies for optimizing combinations of molecularly targeted anticancer agents. Nat Rev Drug Discov 5(8):649–659
26. Feala JD, Cortes J, Duxbury PM, Piermarocchi C, McCulloch AD, Paternostro G (2010) Systems approaches and algorithms for discovery of combinatorial therapies. Wiley Interdiscip Rev Syst Biol Med 2(2):181–193
27. Park M, Nassar M, Vikalo H (2013) Bayesian active learning for drug combinations. IEEE Trans Biomed Eng 60(11):3248–3255
28. Marshall J (2006) Clinical implications of the mechanism of epidermal growth factor receptor inhibitors. Cancer 107(6):1207–1218
29. Adhireksan Z, Davey GE, Campomanes P, Groessl M, Clavel CM, Yu H, Nazarov AA, Yeo HF, Ang WH, Droge P, Rothlisberger U, Dyson PJ, Davey CA (2014) A ligand distinction between two ruthenium-cymen anticancer agents determines protein versus DNA targeting. Nat Commun 5:3462
30. Garber K (2009) Targeting mTOR: something old, something new. J Natl Cancer Inst 101(5):288–290
31. van Beijnum JR, Nowak-Sliwinska P, van den Boezem E, Hautvast P, Buurman WA, Griffioen AW (2013) Tumor angiogenesis is enforced by autocrine regulation of high-mobility group box 1. Oncogene 17(32):363–374
32. Siemerink MJ, Klaassen I, Vogels IM, Griffioen AW, Van Noorden CJ, Schlingemann RO (2012) CD34 marks angiogenic tip cells in human vascular endothelial cell cultures. Angiogenesis 15(1):151–163
33. Nowak-Sliwinska P, van Beijnum JR, van Berkel M, van den Bergh H, Griffioen AW (2010) Vascular regrowth following photodynamic therapy in the chicken embryo chorioallantoic membrane. Angiogenesis 13(4):281–292
34. Tsutsui H, Valamehr B, Hindoyan A, Qiao R, Ding X, Guo S, Witte ON, Liu X, Ho CM, Wu H (2011) An optimized small molecule inhibitor cocktail supports long-term maintenance of human embryonic stem cells. Nat Commun 2:167
35. Yu F, Al-Shyoukh I, Feng J, Li X, Liao CW, Ho CM, Shamma JS, Sun R (2011) Control of Kaposi’s sarcoma-associated herpesvirus reactivation induced by multiple signals. PLoS One 6(6):e20998
36. Weiss A, van Beijnum JR, Bonvin D, Jichlinski P, Dyson PJ, Griffioen AW, Nowak-Sliwinska P (2014) Low-dose angiostatic tyrosine kinase inhibitors improve photodynamic therapy for cancer: lack of vascular normalization. J Cell Mol Med 18:480–491
37. Ding X, Sanchez DJ, Shahangian A, Al-Shyoukh I, Cheng G, Ho CM (2012) Cascade search for HSV-1 combinatorial drugs with high antiviral efficacy and low toxicity. Int J Nanomed 7:2281–2292
38. Stanescu R, Didilescu AC, Jianu AM, Rusu MC (2012) Angiogenesis in the reparatory mucosa of the mandibular edentulous ridge is driven by endothelial tip cells. Rom J Morphol Embryol 53(2):375–378
39. Vrapciu AD, Rusu MC, Voinea LM (2014) Immunohistochemistry of a choroidal melanoma: nestin, CD34 and CD117/c-kit labeling. Rom J Morphol Embryol 55(2):437–442
40. Reuwer AQ, Nowak-Sliwinska P, Mans LA, van der Loos CM, von der Thüsen JH, Twickler MT, Spek CA, Goffin V, Griffioen AW, Borensztajn KS (2012) Functional consequences of prolactin signaling in endothelial cells: A potential link with angiogenesis in pathophysiology? J Cell Mol Med 16(9):2035–2048
41. Weiss A, Berndsen BH, Dubois M, Müller M, Schibli R, Griffioen AW, Dyson PJ, Nowak-Sliwinska P (2014) In vivo anti-tumor activity of the organometallic ruthenium(II)-arene complex [Ru(ɳ6-p-cymene)Cl2(pta)] (RAPTA-C) in human ovarian and colorectal carcinomas. Chem Sci 5:4742–4748
42. Al-Shyoukh I, Yu F, Feng J, Yan K, Dubinett S, Ho CM, Shamma JS, Sun R (2011) Systematic quantitative characterization of cellular responses induced by multiple signals. BMC Syst Biol 5:88
43. Wood K, Nishida S, Sontag ED, Cluzel P (2012) Mechanism-independent method for predicting response to multidrug combinations in bacteria. Proc Natl Acad Sci 109(30):12254–12259
44. Bhargava P, Robinson MO (2011) Development of second-generation VEGFR tyrosine kinase inhibitors: current status. Curr Oncol Rep 13(2):103–111
45. Adhireksan Z, Davey GE, Campomanes P, Groessl M, Clavel CM, Yu H, Nazarov AA, Yeo CH, Ang WH, Droge P, Rothlisberger U, Dyson PJ, Davey CA (2014) Ligand substitutions between ruthenium-cymene compounds can control protein versus DNA targeting and anticancer activity. Nat Commun 5:3462
46. Martin M, Potente M, Janssens V, Vertommen D, Twizere JC, Rider MH, Goris J, Dimmeler S, Kettmann R, Dequiedt F (2008) Protein phosphatase 2A controls the activity of histone deacetylase 7 during T cell apoptosis and angiogenesis. Proc Natl Acad Sci 105(12):4727–4732
47. Hellebrekers DM, Castermans K, Vire E, Dings RP, Hoebers NT, Mayo KH, Oude Egbrink MG, Molema G, Fuks F, van Engeland M, Griffioen AW (2006) Epigenetic regulation of tumor endothelial cell anergy: silencing of intercellular adhesion molecule-1 by histone modifications. Cancer Res 66(22):10770–10777
48. Rossig L, Li H, Fisslthaler B, Urbich C, Fleming I, Forstermann U, Zeiher AM, Dimmeler S (2002) Inhibitors of histone deacetylation downregulate the expression of endothelial nitric oxide synthase and compromise endothelial cell function in vasorelaxation and angiogenesis. Circ Res 91(9):837–844
49. Bianco R, Garofalo S, Rosa R, Damiano V, Gelardi T, Daniele G, Marciano R, Ciardiello F, Tortora G (2008) Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs. Br J Cancer 98(5):923–930
50. Rao RD, Mladek AC, Lamont JD, Goble JM, Erlichman C, James CD, Sarkaria JN (2005) Disruption of parallel and converging signaling pathways contributes to the synergistic antitumor effects of simultaneous mTOR and EGFR inhibition in GBM cells. Neoplasia 7(10):921–929
51. Bauman JE, Arias-Pulido H, Lee SJ, Fekrazad MH, Ozawa H, Fertig E, Howard J, Bishop J, Wang H, Olson GT, Spafford MJ, Jones DV, Chung CH (2013) A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma. Oral Oncol 49(5):461–467
52. Wen PY, Chang SM, Lamborn KR, Kuhn JG, Norden AD, Cloughesy TF, Robins HI, Lieberman FS, Gilbert MR, Mehta MP, Drappatz J, Groves MD, Santagata S, Ligon AH, Yung WK, Wright JJ, Dancey J, Aldape KD, Prados MD, Ligon KL (2014) Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02. Neuro-oncol 16(4):567–578
53. Hinow P, Gerlee P, McCawley LJ, Quaranta V, Ciobanu M, Wang S, Graham JM, Ayati BP, Claridge J, Swanson KR, Loveless M, Anderson AR (2009) A spatial model of tumor-host interaction: application of chemotherapy. Math Biosci Eng 6(3):521–546
54. Reardon DA, Cheresh D (2011) Cilengitide: a prototypic integrin inhibitor for the treatment of glioblastoma and other malignancies. Genes Cancer 2(12):1159–1165
55. Almokadem S, Belani CP (2012) Volociximab in cancer. Expert Opin Biol Ther 12(2):251–257
56. Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307(5706):58–62
57. Weiss A, Bonvin D, Berndsen B, Sherrer E, Dyson PJ, Griffioen AW, Nowak-Sliwinska P (2015) Angiostatic treatment prior to chemo- or photodynamic therapy improves anti-tumor efficacy. Sci Rep 5(8990):1–8